Yecuris Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
26
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
7
Yecuris General Information
Description
Developer of chimeric animal models designed to provide researchers with actionable insights into liver-specific questions at the cellular, tissue, and animal level. The company promotes the use of chimeric animal technologies to answer critical questions in drug metabolism, clinical safety assessment, cancer biology, and gene and cell therapy, enabling researchers to find treatments and cures for metabolic and liver disorders ranging from cirrhosis and hepatitis to inborn errors and gene correction.
Contact Information
Website
www.yecuris.com(Operating Subsidiary)
Corporate Office
- PO Box 4645
- Tualatin, OR 97062
- United States
Corporate Office
- PO Box 4645
- Tualatin, OR 97062
- United States
Yecuris Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Yecuris Comparisons
Industry
Financing
Details
Yecuris Competitors (15)
One of Yecuris’s 15 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Thetis Pharmaceuticals | Venture Capital-Backed | Essex, CT | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Laurent Pharma | Venture Capital-Backed | Montreal, Canada | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom |
Yecuris Patents
Yecuris Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2014525248-A | Fumaryl acetoacetate hydrolase (fah) deficient and immunodeficient rats and their use | Active | 26-Aug-2011 | ||
| JP-6484444-B2 | Fumaryl acetoacetate hydrolase (fah) deficient and immunodeficient rats and their use | Active | 26-Aug-2011 | ||
| JP-6573924-B2 | Fumaryl acetoacetate hydrolase (fah) deficient and immunodeficient rats and their use | Active | 26-Aug-2011 | ||
| EP-2747551-A1 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Active | 26-Aug-2011 | ||
| EP-2747551-A4 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Active | 26-Aug-2011 | A01K67/0276 |
Yecuris Signals
Yecuris Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Yecuris FAQs
-
When was Yecuris founded?
Yecuris was founded in 2007.
-
Where is Yecuris headquartered?
Yecuris is headquartered in Tualatin, OR.
-
What is the size of Yecuris?
Yecuris has 26 total employees.
-
What industry is Yecuris in?
Yecuris’s primary industry is Biotechnology.
-
Is Yecuris a private or public company?
Yecuris is a Private company.
-
What is Yecuris’s current revenue?
The current revenue for Yecuris is .
-
How much funding has Yecuris raised over time?
Yecuris has raised $3M.
-
Who are Yecuris’s investors?
NIH Office of the Director, Starveups, and U.S. Department of Health and Human Services have invested in Yecuris.
-
Who are Yecuris’s competitors?
Aqualung Therapeutics, Thetis Pharmaceuticals, Enterprise Therapeutics, Laurent Pharma, and Verona Pharma are some of the 15 competitors of Yecuris.
-
When was Yecuris acquired?
Yecuris was acquired on 27-Dec-2023.
-
Who acquired Yecuris?
Yecuris was acquired by Janvier Labs.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process